Markets
MDT

Cardinal Health Unveils Positive Data for INCRAFT Stent Graft

A generic image of a newspaper with Stock Market as the Headline.
Credit: Shutterstock photo

Cordis, a Cardinal Health, Inc.CAH company, recently announced positive four-year data from its INNOVATION Trial at the 2015 VEITHsymposium held in New York City. The clinical data reaffirmed the advantages of INCRAFT Stent Graft System for patients with abdominal aortic aneurysms (AAA) even after four years of treatment.

The INCRAFT AAA Stent-Graft System is an advanced Endovascular Aneurysm Repair (EVAR) technology designed for the treatment of infrarenal abdominal aortic aneurysms. The product boasts advanced technologies intended for sturdiness, conformability, accuracy of placement and sealing without the requirement for polymers.

The INNOVATION Trial was aimed at evaluating the effectiveness of the device, with investigational sites set up in Germany and Italy. The results from the clinical study established that four years after treatment, the INCRAFT System performed quite satisfactorily with over 97% freedom from endoleaks and no stent graft migrations.

It is to be noted that the INCRAFT System is already commercially available across Europe, Canada, Mexico, Colombia and Brazil, whereas it is accessible for investigational device use in the U.S. and Japan.

We believe that positive data in favor of the product will pave the way for a faster FDA approval, which in turn, will eventually ramp up sales at the company. According to estimates, 24 million people suffer from AAA globally. This indicates high demand potential for aortic stent grafts and indicates substantial growth opportunities for Cardinal Health, going ahead.

Nevertheless, Cardinal Health is expected to face considerable competition in the EVAR market. We note that Medtronic's MDT Endurant II AAA Stent Graft System has been gaining ground in the market for quite some time now. The original Endurant AAA Stent Graft had received the FDA approval in Dec 2010. The next-generation Endurant II AAA Stent Graft received the CE Mark in Dec 2011, replacing the preceding version in Western Europe.

Zacks Rank and Key Picks

Currently, Cardinal Health carries a Zacks Rank #1 (Strong Buy). Other top-ranked stocks in the medical sector are Masimo MASI and Natus Medical BABY , both with a Zacks Rank #1 as well.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MEDTRONIC (MDT): Free Stock Analysis Report

CARDINAL HEALTH (CAH): Free Stock Analysis Report

MASIMO CORP (MASI): Free Stock Analysis Report

NATUS MEDICAL (BABY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MDT NTUS MASI CAH

Other Topics

Stocks

Latest Markets Videos